The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology

• DOI: 10.1016/j.esmoop.2024.102981
• Publication Date: 2024-04-12T22:39:25Z
• Authors: T. Kubo; K. Sunami; T. Koyama; M. Kitami; Y. Fujiwara; S. Kondo; K. Yonemori; E. Noguchi; C. Morizane; Y. Goto; A. Maejima; S. Iwasa; T. Hamaguchi; A. Kawai; K. Namikawa; A. Arakawa; M. Sugiyama; M. Ohno; T. Yoshida; N. Hiraoka; A. Yoshida; M. Yoshida; T. Nishino; E. Furukawa; D. Narushima; M. Nagai; M. Kato; H. Ichikawa; Y. Fujiwara; T. Kohno; N. Yamamoto
• Keywords: Cancer Treatment

•Of 507 patients who underwent CGP, 12.2% received genomically matched therapies with a 32.3% ORR.•The PFS ratios (>1.3) were observed in 46.3% (19/41) of the evaluated patients.•Patients rare cancers benefited most from tumor mutation profiling.•Early-line treatments following profiling increase therapeutic benefit, irrespective type. BackgroundComprehensive genome (CGP) serves as guide for suitable cancer. However, little is known about impact timing and types cancer on benefit CGP.Materials methodsA single hospital-based pan-cancer prospective study (TOP-GEAR; UMIN000011141) was conducted to examine CGP respect Patients advanced solid tumors (>30 types) either progressed or without standard genotyped using test. The subjects followed up median duration 590 days response, progression-free survival (PFS), ratio, factors associated response.ResultsAmong patients, 62 (12.2%) an overall response rate (ORR) 32.3%. (≥1.3) patients. proportion receiving such cohort lower than that non-rare (9.6% 17.4%, respectively; P = 0.010). ORR higher (43.8% 20.0%, 0.046). Moreover, first second line after test third later lines (62.5% 21.7%, 0.003). Rare early-line treatment significantly independently multivariable analysis (P 0.017 0.004, respectively).ConclusionPatients preferentially by increasing chances therapies. Early-line types. Comprehensive CGP. A response. Among respectively).